Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

@article{Zhang2007VasoactiveIP,
  title={Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.},
  author={Kaijun Zhang and Mohan R Aruva and Nylla Shanthly and Christopher A. Cardi and Chirag A Patel and Satish Rattan and Gregory Cesarone and Eric Wickstrom and Mathew L. Thakur},
  journal={Regulatory peptides},
  year={2007},
  volume={144 1-3},
  pages={91-100}
}
Vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide have high affinity for VPAC1, VPAC2 and PAC1 receptors overexpressed on human cancer cells. Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity. The ultimate goal is to utilize (64)Cu analogues for positron emission tomography (PET) imaging of breast cancers in humans… CONTINUE READING